Search Results - agonists%2fpromoters

13 Results

Sort By:

Farnesylation of PARIS Prevents Dopaminergic Neurodegeneration in Models of Parkinson’s Disease

Unmet Need: Parkinson's disease (PD) is an incurable progressive neurodegenerative disease. It is characterized clinically by motor dysfunction that is due to the preferential loss of dopaminergic neurons in the brain. Current treatment strategies for PD are mainly limited to the management of the motor symptoms with drugs such as L-DOPA or dopamine...

Published: 5/9/2024 | Inventor(s): Ted Dawson, Valina Dawson, Joo-Ho Shin, Yunjong Lee, Areum Jo

Keywords(s): Agonists/Promoters, CNS and Neurological Disorders, Disease Indication, Non-novel, Off-the-shelf, Parkinson's Disease, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Parkinson's Disease

M4N and Temozolomide Combination Therapy for Glioblastoma multiforme (GBM)

Unmet NeedGlioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and remains one of the most aggressive types of malignancies. The mainstay of GBM treatment is surgery, radiation and adjuvant chemotherapy using temozolomide (TMZ). While treatment options have incrementally improved, survival rates remains dismal. Only...

Published: 5/9/2024 | Inventor(s): Ru Chih Huang, Jong ho Chun, Yu-Ling Lin, Yu-Chuan Liang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai

Keywords(s): Agonists/Promoters, Brain Cancer, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Glioblastoma, Glioma, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Brain Cancer

Discovery of Novel Compounds that Enhance Enteric Nervous System Function

Unmet needNecrotizing enterocolitis (NEC), a condition of newborns in which a portion of the bowel dies. NEC affects one in 1000-4000 births, or about 10% of preterm children and is associated with an overall mortality of up to 40%. NEC is thought to be caused by defective bacterial-host signaling during colonization of the intestine with bacteria,...

Published: 5/9/2024 | Inventor(s): David Hackam, Peng Lu, Chhinder Sodhi

Keywords(s): Agonists/Promoters, Disease Indication, Inflammatory Disorders, Necrotizing Enterocolitis (NEC), Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Clinical and Disease Specializations > Inflammation > Necrotizing Enterocolitis

Use of AHR Agonists to Prevent or Treat NEC in Premature Infants

UNMET NEED: Necrotizing enterocolitis (NEC) is the leading cause of death from gastrointestinal disease in premature infants. The main risk factors for the development of NEC are prematurity, bacterial colonization and administration of formula feeds, which in the setting of an abnormal microbiome lead to enhanced signaling via toll like receptor 4...

Published: 5/9/2024 | Inventor(s): David Hackam, Chhinder Sodhi, Jun Liu, Peng Lu

Keywords(s): Agonists/Promoters, Disease Indication, Gastrointestinal Disorders, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Targeting liver nuclear receptors as a treatment for Wilsons disease

Wilson disease is a hepato-neurologic disorder caused by mutations in the gene ATP7B and accumulation of copper in tissues, predominantly in the liver. The disease is lethal, unless treated. Current life-long treatment involves copper chelation or copper replacement using Zn. Both procedures alleviate major symptoms but side effects are frequent and...

Published: 5/9/2024 | Inventor(s): Svetlana Lutsenko, James Hamilton

Keywords(s): Agonists/Promoters, Biomarker, Disease Indication, Genetic Disorders, Liver, Liver Transplant, Mechanism-of-action Biomarker, Non-novel, Off-the-shelf, Predicted Novelty, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Transplants, Wilson's Disease

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Genetic Diseases > Wilson's Disease, Clinical and Disease Specializations > Rare Diseases, Clinical and Disease Specializations > Transplantation > Liver Transplant, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Genetic Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Transplantation

Method for Treating Refractory Seizures Using a Novel Therapeutic Approach

Technology OverviewThe invention provides novel pharmaceutical interventions that convert phenobarbital (PB)-resistant seizures into phenobarbital responsive seizures in neonates. We have shown that unlike in adult brains, expression of a transport protein in the neonatal brain is much lower and undergoes further down-regulation following an ischemic...

Published: 5/9/2024 | Inventor(s): Shilpa Kadam

Keywords(s): Agonists/Promoters, CNS and Neurological Disorders, Disease Indication, Epilepsy, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology > Epilepsy, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities

Compounds and Methods to Decrease Obesity-related Hepatic Fat Accumulation and Serum Glucose

Technology DescriptionResearchers at Johns Hopkins have identified that valproic acid (VPA) and its metabolites may be useful for the treatment of obesity and related metabolic diseases (e.g., type 2 diabetes, fatty liver disease).VPA and its cytochrome P450- and beta-oxidation-dependent metabolites activate AMP-activated protein kinase (AMPK), which...

Published: 5/9/2024 | Inventor(s): Lindsay Avery, Namandje Bumpus

Keywords(s): Agonists/Promoters, Disease Indication, Metabolic Disorders, Non-novel, Obesity, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases > Obesity, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Metabolic Diseases, Technology Classifications > Therapeutic Modalities

Activators of Myosin II for Modulating Cell Mechanics

C12770: Novel Panel of Myosin II Activators for Disease Therapy and Tissue EngineeringNovelty:A panel of myosin II activators developed to treat disease and useful for tissue engineering in regenerative medicine.Value Proposition:Changes in cellular mechanics due to impaired activity of myosin II, a motor protein essential for cell division, motility,...

Published: 5/9/2024 | Inventor(s): Douglas Robinson, Alexandra Surcel, Win Pin Ng, Caren Freel Meyers

Keywords(s): Agonists/Promoters, Cancers, Disease Indication, Non-novel, Pancreatic Cancer, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Technology Classifications > Medical Devices > Regenerative Medicine, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

Small Molecule Malarial Aldolase-trap Enhancers and Glideosome Inhibitors

C12661: Novel Anti-Malarial Compounds and CompositionsNovelty: This technology provides new classes of anti-malarial compounds and a method to identify such compounds.Value Proposition: Nearly half the worlds population is at risk of acquiring malaria, which is caused by the Plasmodium family of protozoan parasites. Common drugs used to treat malaria...

Published: 5/9/2024 | Inventor(s): Sondra Nemetski, Timothy Cardozo, Jurgen Bosch

Keywords(s): Agonists/Promoters, Antagonists/Inhibitors, Disease Indication, Infectious Diseases, Malaria, Novel, Parasitic Infections, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Malaria, Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities

A Neuroprotective Agent with Applicability to Glaucoma, Optic Nerve Diseases, and other Neurodegenerations

C10454: Known Drug found to have applicability in the area of glaucoma, optic nerve diseases, and other neurodegenerationsValue Proposition: Key Features • Provides treatment for glaucoma, other optic nerve diseases, and potentially any disease with neuronal dysfunction or loss. • Exploits an FDA approved drug, which may reduce clinical hurdles and...

Published: 5/9/2024 | Inventor(s): Zhiyong Yang, Cynthia Berlinicke, Harry Quigley, Donald Zack

Keywords(s): Agonists/Promoters, CNS and Neurological Disorders, Disease Indication, Eye Disorders, Glaucoma, Non-novel, Optic Nerve Diseases, Optic Neuropathy, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Ophthalmology > Glaucoma, Clinical and Disease Specializations > Ophthalmology > Optic Neuropathy, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Ophthalmology, Technology Classifications > Therapeutic Modalities

1 2